Post-marketing observational surveillance study to evaluate pregnancy outcomes among women who receive Heplisav-B or Engerix-B (DV2-HBV-28)First published 02/09/2024 Last updated 02/09/2024 EU PAS number: EUPAS1000000304StudyFinalised